Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics' shares released from escrow

Zelda has a human clinical trial focused on insomnia, autism and eczema.
Zelda Therapeutics' shares released from escrow
Dr. Stewart Washer

Zelda Therapeutics Ltd (ASX:ZLD) now has an additional 111.6 million shares available for trade on the ASX, following the end of an escrow period.

Zelda now has 530 million shares on issue.

The company is developing a range of cannabinoid-based formulations to treat medical conditions, and Dr. Stewart Washer, executive director, recently presented the next steps to investors.

WATCH NOW: Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions

View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use